Dasatinib 98% (HPLC) - 50 Mg - Sigma
Código: 16925
Dasatinib ≥98% (HPLC)
Synonym: BMS 354825, BMS-354825, BMS354825, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
|
assay |
≥98% (HPLC) |
|
form |
powder |
|
color |
white to beige |
|
solubility |
DMSO: 2 mg/mL, clear |
|
storage temp. |
−20°C |
|
SMILES string |
CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCO)=N1 |
|
InChI |
1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) |
|
InChI key |
ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
|
Gene Information |
human ... ABL1(25), BLK(640), EPHA2(1969), FGR(2268), FRK(2444), FYN(2534), HCK(3055), KIT(3815), LCK(3932), LYN(4067), PDGFRB(5159), SRC(6714), SRMS(6725), YES1(7525) |
Descrição
Biochem/physiol Actions
Dasatinib is an orally available and highly potent pan-Src/Bcr-Abl inhibitor (Ki values are 16 and 30 pM, respectively. It also inhibits Lck, Fyn, c-kit and Yes with IC50 values in the subnanomolar range. Dasatinib exhibits potent antitumor activities and is used for treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).
